A guide on using Dulaglutide for T2D

Date Published: 
Wednesday, September 8, 2021
Duration: 
31:45
Download MP3 File

Dr Rinki Murphy discusses type 2 diabetes management with a focus on GLP- 1 receptor agonists. We discuss the indications for use and how to use dulaglutide now that it has medsafe approval.

 

Topics:

  • 01:32 Lifestyle interventions and weight reduction
  • 04:27 how do we best approach pharmacological management?
  • 06:52 GLP-1 receptor agonists. How do these medication work exactly?
  • 08:35 advantages of these medications in the diabetic patient.
  • 10:00 What cohort will benefit from these medications?
  • 11:16 benefits beyond diabetes
  • 12:15 When should we be cautious about prescribing these medications?
  • 12:59 Do we have to worry about hypoglycemia?
  • 13:56 How do these new medications fit in our prescribing pathway for diabetes?
  • 16:43 What GLP-1 receptor agonists are currently available in NZ?
  • 17:45 Why would we choose Trulicity over another GLP-1 receptor agonist?
  • 19:26 Who is it funded for?
  • 21:18 Dosing titration and monitoring
  • 28:18 What are the common side effects?
  • 19:14 Weigth loss
  • 30:00 Take-home messages

 

Take-home messages

  • Assess all people with T2D for CKD with UACR and sCR, and consider prescribing SGLT2i (Jardiance is funded under SA) for long term renal benefit, along with ACEi/ARB, and other BP lowering meds as needed.  
  • Assess all people with T2D for CVD risk or past IHD, and consider prescribing GLP1RA (along with statins, BP lowering, smoking cessation)
  • If not suitable or eligible for funding for SGLT2i then consider prescribing GLP1RA or vice versa.  
  • Stop vildagliptin (Galvus) when using GLP1RA.  Trulicity 1.5mg SC weekly is funded under SA.  
  • May use both Jardiance and Trulicity but only one can be reimbursed through SA funding.

 

Resources

 

Presenter

Rinki Murphy
Diabetes Physician

Rinki is an Associate Professor in Medicine at the University of Auckland and Principle investigator at the Maurice Wilkins Centre for Biodiscovery.  She is a diabetologist at Auckland and Counties Manukau DHBs.

This webinar is supported by Lilly:

Recognition of Learning Activities

Complete and submit the learning reflection form for CPD/MOPS points provided by The Royal New Zealand College of General Practitioners below for recognition of learning activities.

Learning Reflection Form

www.rnzcgp.org.nz

This presentation is intended for qualified health practitioners professional development and should not be relied upon for any other purpose. Any opinions offered are those of the presenter or other speaker and do not necessarily represent the views of Goodfellow Unit.